<p>Replimune Group（納斯達克代碼：REPL - 獲取免費報告）預計將在 2026 年 2 月 11 日星期三市場開盤前發佈其 2026 年第三季度財報。分析師預計 Replimune Group 本季度每股收益為（$0.85）。各方可以查看公司即將發佈的 2026 年第三季度財報中的信息，以獲取關於定於 2026 年 2 月 3 日星期二上午 8:00（東部時間）的電話會議的最新細節。</p>
<p>獲取 <strong>Replimune Group</strong> 的提醒：</p>
<ul>
<li>按表現排名的最佳股票選擇 AI</li>
</ul>
<p>Replimune Group（納斯達克代碼：REPL - 獲取免費報告）上次於 2026 年 2 月 3 日星期二公佈季度財報。該公司報告每股收益（EPS）為（$0.77），超出市場共識預期的（$0.85）$0.08。分析師平均預計 Replimune Group 在當前財年每股收益為$-3，在下一個財年每股收益也為$-3。</p>
<h2>Replimune Group 股票上漲 5.9%</h2>
<p>REPL 股票在星期三以$7.38 開盤。該公司的流動比率為 6.31，速動比率為 6.31，債務與股本比率為 0.26。該公司 50 日移動平均為$8.94，200 日移動平均為$7.22。Replimune Group 的 12 個月最低價為$2.68，最高價為$14.80。該公司的市值為 5.7889 億美元，市盈率為-2.13，貝塔值為 0.73。</p>
<h2>Replimune Group 內部活動</h2>
<p>在 Replimune Group 的其他新聞中，董事 Kapil Dhingra 於 2025 年 12 月 9 日星期二出售了 3,169 股該股票。股票以平均價格$10.40 出售，總交易額為$32,957.60。該交易在向證券交易委員會提交的文件中披露，該文件可通過 SEC 網站訪問。此外，內部人士 Christopher Sarchi 於 2025 年 11 月 17 日星期一出售了 5,208 股該公司的股票。股票以平均價格$9.10 出售，總交易額為$47,392.80。交易完成後，該內部人士直接持有 123,088 股公司股票，價值$1,120,100.80。這筆交易代表其持股比例減少了 4.06%。該交易的 SEC 文件提供了更多信息。在過去的九十天裏，內部人士出售了價值$257,607 的 25,625 股公司股票。5.20% 的股票由公司內部人士持有。</p>
<h2>機構投資者對 Replimune Group 的看法</h2>
<p>一些機構投資者最近調整了對該公司的持股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度將其在 Replimune Group 的持股增加了 17.6%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.現在擁有 44,352 股該公司的股票，價值$435,000，在此期間又購買了 6,653 股。Millennium Management LLC 在第一季度將其在 Replimune Group 的持股增加了 2.8%。Millennium Management LLC 現在擁有 1,223,236 股該公司的股票，價值$11,927,000，在上個季度又收購了 33,574 股。高盛集團（Goldman Sachs Group Inc.）在第一季度將其在 Replimune Group 的持股增加了 20.9%。高盛集團現在擁有 690,167 股該公司的股票，價值$6,729,000，在此期間又購買了 119,145 股。Rhumbline Advisers 在第二季度將其在 Replimune Group 的持股增加了 6.9%。Rhumbline Advisers 現在擁有 102,005 股該公司的股票，價值$948,000，在此期間又購買了 6,616 股。最後，Sei Investments Co.在第二季度將其在 Replimune Group 的持股增加了 149.5%。Sei Investments Co.現在擁有 30,478 股該公司的股票，價值$283,000，在上個季度又購買了 18,263 股。92.53% 的股票由機構投資者和對沖基金持有。</p>
<h2>分析師升級和降級</h2>
<p>幾位股票研究分析師最近對該公司發表了評論。Leerink Partners 將 Replimune Group 的評級從 “市場表現” 上調至 “跑贏大盤”，並在 2025 年 10 月 20 日的報告中將其目標價從$3.00 提高至$13.00。Wedbush 將 Replimune Group 的評級從 “中性” 上調至 “跑贏大盤”，並在 2025 年 10 月 20 日的研究報告中將其目標價從$4.00 提高至$18.00。HC Wainwright 將 Replimune Group 的評級從 “中性” 上調至 “買入”，並在 2025 年 10 月 27 日的報告中設定了$12.00 的目標價。Weiss Ratings 在 2025 年 12 月 29 日的報告中重新發布了對 Replimune Group 股票的 “賣出（d-）” 評級。最後，摩根大通（JPMorgan Chase &amp; Co.）將 Replimune Group 的股票評級從 “減持” 上調至 “中性”，並在 2025 年 10 月 20 日的研究報告中設定了$11.00 的目標價。六位投資分析師對該股票給予了買入評級，兩位給予了持有評級，兩位給予了賣出評級。根據 MarketBeat.com，該公司的共識評級為 “持有”，平均目標價為$9.75。</p>
<p><strong>閲讀我們關於 Replimune Group 的最新報告</strong></p>
<h2>關於 Replimune Group</h2>
<p>（獲取免費報告）</p>
<p>Replimune Group, Inc 是一家臨牀階段的生物技術公司，專注於開發下一代腫瘤溶解免疫療法以治療實體腫瘤。該公司的專有 “RP” 平台利用基因工程改造的單純皰疹病毒 1 型（HSV-1）載體，攜帶免疫調節藥物，選擇性地感染、在癌細胞內複製並摧毀癌細胞，同時刺激全身抗腫瘤免疫反應。</p>
<p>Replimune 的主要候選藥物 RP1，結合了 GM-CSF 和融合蛋白，以增強直接腫瘤溶解和免疫激活。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Replimune Group</li>
<li>你的銀行賬户不再安全</li>
<li>雷·達里奧建議買黃金。我建議每月從中獲得收入</li>
<li>每天一次，持續一小時</li>
<li>[顯而易見的黃金投資]: “給我一個更好的投資。”</li>
<li>一位前 CIA 特工對即將到來的崩潰的看法</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVQTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVQTA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 $1,000 在 Replimune Group 嗎？</h2>
<p>在考慮 Replimune Group 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛的市場注意到之前購買的股票……而 Replimune Group 並不在名單上。</p>
<p>雖然 Replimune Group 目前在分析師中被評為持有，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

IBBQ

2 倍做多納斯達克生物技術 ETF - ProShares

動態生物技術與基因組 ETF - Invesco

醫藥突破 ETF - ALPS

生物科技 ETF - VanEck Vectors

標普生物技術 3 倍做空 - Direxion

REPL

納斯達克生物科技指數 ETF - iShares Nasdaq

紐交所高增長板生物技術指數 ETF - First Trust

<p>Replimune Group（納斯達克代碼：REPL）將於 2 月 11 日發佈 2026 年第三季度財報，分析師預計每股虧損 0.85 美元。該公司此前報告每股虧損 0.77 美元，超出預期。REPL 股票上漲 5.9%，開盤價為 7.38 美元。內部交易活動包括董事的股票出售，機構投資者持有 92.53% 的股份。近期分析師的評級上調顯著提高了價格目標，一些公司將其評級上調至 “跑贏大盤”，目標價高達 18.00 美元</p>

<p>Replimune Group (NASDAQ:REPL - Get Free Report) is expected to be issuing its Q3 2026 results before the market opens on Wednesday, February 11th. Analysts expect Replimune Group to post earnings of ($0.85) per share for the quarter. Parties may review the information on the company's upcoming Q3 2026 earning report for the latest details on the call scheduled for Tuesday, February 3, 2026 at 8:00 AM ET.</p>
<div class="lb-trans"><p>Replimune Group（納斯達克代碼：REPL - 獲取免費報告）預計將在 2026 年 2 月 11 日星期三市場開盤前發佈其 2026 年第三季度財報。分析師預計 Replimune Group 本季度每股收益為（$0.85）。各方可以查看公司即將發佈的 2026 年第三季度財報中的信息，以獲取關於定於 2026 年 2 月 3 日星期二上午 8:00（東部時間）的電話會議的最新細節。</p>
</div><p>Get <strong>Replimune Group</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Replimune Group</strong> 的提醒：</p>
</div><ul>
<li>The Best AI for Picking Stocks, Ranked by Performance</li>
</ul>
<div class="lb-trans"><ul>
<li>按表現排名的最佳股票選擇 AI</li>
</ul>
</div><p>Replimune Group (NASDAQ:REPL - Get Free Report) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported ($0.77) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.08. On average, analysts expect Replimune Group to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>Replimune Group（納斯達克代碼：REPL - 獲取免費報告）上次於 2026 年 2 月 3 日星期二公佈季度財報。該公司報告每股收益（EPS）為（$0.77），超出市場共識預期的（$0.85）$0.08。分析師平均預計 Replimune Group 在當前財年每股收益為$-3，在下一個財年每股收益也為$-3。</p>
</div><h2>Replimune Group Stock Up 5.9%</h2>
<div class="lb-trans"><h2>Replimune Group 股票上漲 5.9%</h2>
</div><p>REPL stock opened at $7.38 on Wednesday. The company has a current ratio of 6.31, a quick ratio of 6.31 and a debt-to-equity ratio of 0.26. The firm has a 50-day moving average of $8.94 and a two-hundred day moving average of $7.22. Replimune Group has a 12 month low of $2.68 and a 12 month high of $14.80. The company has a market cap of $578.89 million, a price-to-earnings ratio of -2.13 and a beta of 0.73.</p>
<div class="lb-trans"><p>REPL 股票在星期三以$7.38 開盤。該公司的流動比率為 6.31，速動比率為 6.31，債務與股本比率為 0.26。該公司 50 日移動平均為$8.94，200 日移動平均為$7.22。Replimune Group 的 12 個月最低價為$2.68，最高價為$14.80。該公司的市值為 5.7889 億美元，市盈率為-2.13，貝塔值為 0.73。</p>
</div><h2>Insider Activity at Replimune Group</h2>
<div class="lb-trans"><h2>Replimune Group 內部活動</h2>
</div><p>In other Replimune Group news, Director Kapil Dhingra sold 3,169 shares of the stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $10.40, for a total transaction of $32,957.60. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, insider Christopher Sarchi sold 5,208 shares of the business's stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $9.10, for a total transaction of $47,392.80. Following the completion of the sale, the insider directly owned 123,088 shares in the company, valued at $1,120,100.80. This trade represents a 4.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 25,625 shares of company stock worth $257,607. 5.20% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在 Replimune Group 的其他新聞中，董事 Kapil Dhingra 於 2025 年 12 月 9 日星期二出售了 3,169 股該股票。股票以平均價格$10.40 出售，總交易額為$32,957.60。該交易在向證券交易委員會提交的文件中披露，該文件可通過 SEC 網站訪問。此外，內部人士 Christopher Sarchi 於 2025 年 11 月 17 日星期一出售了 5,208 股該公司的股票。股票以平均價格$9.10 出售，總交易額為$47,392.80。交易完成後，該內部人士直接持有 123,088 股公司股票，價值$1,120,100.80。這筆交易代表其持股比例減少了 4.06%。該交易的 SEC 文件提供了更多信息。在過去的九十天裏，內部人士出售了價值$257,607 的 25,625 股公司股票。5.20% 的股票由公司內部人士持有。</p>
</div><h2>Institutional Investors Weigh In On Replimune Group</h2>
<div class="lb-trans"><h2>機構投資者對 Replimune Group 的看法</h2>
</div><p>A number of institutional investors have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Replimune Group by 17.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,352 shares of the company's stock valued at $435,000 after buying an additional 6,653 shares during the period. Millennium Management LLC grew its position in Replimune Group by 2.8% in the 1st quarter. Millennium Management LLC now owns 1,223,236 shares of the company's stock valued at $11,927,000 after acquiring an additional 33,574 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in Replimune Group by 20.9% during the first quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company's stock worth $6,729,000 after purchasing an additional 119,145 shares during the period. Rhumbline Advisers increased its stake in Replimune Group by 6.9% during the second quarter. Rhumbline Advisers now owns 102,005 shares of the company's stock worth $948,000 after purchasing an additional 6,616 shares during the period. Finally, Sei Investments Co. lifted its position in shares of Replimune Group by 149.5% during the second quarter. Sei Investments Co. now owns 30,478 shares of the company's stock worth $283,000 after purchasing an additional 18,263 shares in the last quarter. 92.53% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些機構投資者最近調整了對該公司的持股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度將其在 Replimune Group 的持股增加了 17.6%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.現在擁有 44,352 股該公司的股票，價值$435,000，在此期間又購買了 6,653 股。Millennium Management LLC 在第一季度將其在 Replimune Group 的持股增加了 2.8%。Millennium Management LLC 現在擁有 1,223,236 股該公司的股票，價值$11,927,000，在上個季度又收購了 33,574 股。高盛集團（Goldman Sachs Group Inc.）在第一季度將其在 Replimune Group 的持股增加了 20.9%。高盛集團現在擁有 690,167 股該公司的股票，價值$6,729,000，在此期間又購買了 119,145 股。Rhumbline Advisers 在第二季度將其在 Replimune Group 的持股增加了 6.9%。Rhumbline Advisers 現在擁有 102,005 股該公司的股票，價值$948,000，在此期間又購買了 6,616 股。最後，Sei Investments Co.在第二季度將其在 Replimune Group 的持股增加了 149.5%。Sei Investments Co.現在擁有 30,478 股該公司的股票，價值$283,000，在上個季度又購買了 18,263 股。92.53% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師升級和降級</h2>
</div><p>Several equities research analysts recently commented on the company. Leerink Partners raised Replimune Group from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and increased their price target for the company from $3.00 to $13.00 in a report on Monday, October 20th. Wedbush raised Replimune Group from a &#34;neutral&#34; rating to an &#34;outperform&#34; rating and raised their target price for the stock from $4.00 to $18.00 in a research note on Monday, October 20th. HC Wainwright upgraded Replimune Group from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and set a $12.00 price target on the stock in a report on Monday, October 27th. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Replimune Group in a report on Monday, December 29th. Finally, JPMorgan Chase &amp; Co. upgraded shares of Replimune Group from an &#34;underweight&#34; rating to a &#34;neutral&#34; rating and set a $11.00 price objective for the company in a research report on Monday, October 20th. Six investment analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of &#34;Hold&#34; and an average target price of $9.75.</p>
<div class="lb-trans"><p>幾位股票研究分析師最近對該公司發表了評論。Leerink Partners 將 Replimune Group 的評級從 “市場表現” 上調至 “跑贏大盤”，並在 2025 年 10 月 20 日的報告中將其目標價從$3.00 提高至$13.00。Wedbush 將 Replimune Group 的評級從 “中性” 上調至 “跑贏大盤”，並在 2025 年 10 月 20 日的研究報告中將其目標價從$4.00 提高至$18.00。HC Wainwright 將 Replimune Group 的評級從 “中性” 上調至 “買入”，並在 2025 年 10 月 27 日的報告中設定了$12.00 的目標價。Weiss Ratings 在 2025 年 12 月 29 日的報告中重新發布了對 Replimune Group 股票的 “賣出（d-）” 評級。最後，摩根大通（JPMorgan Chase &amp; Co.）將 Replimune Group 的股票評級從 “減持” 上調至 “中性”，並在 2025 年 10 月 20 日的研究報告中設定了$11.00 的目標價。六位投資分析師對該股票給予了買入評級，兩位給予了持有評級，兩位給予了賣出評級。根據 MarketBeat.com，該公司的共識評級為 “持有”，平均目標價為$9.75。</p>
</div><p><strong>Read Our Latest Report on Replimune Group</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 Replimune Group 的最新報告</strong></p>
</div><h2>About Replimune Group</h2>
<div class="lb-trans"><h2>關於 Replimune Group</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company's proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.</p>
<div class="lb-trans"><p>Replimune Group, Inc 是一家臨牀階段的生物技術公司，專注於開發下一代腫瘤溶解免疫療法以治療實體腫瘤。該公司的專有 “RP” 平台利用基因工程改造的單純皰疹病毒 1 型（HSV-1）載體，攜帶免疫調節藥物，選擇性地感染、在癌細胞內複製並摧毀癌細胞，同時刺激全身抗腫瘤免疫反應。</p>
</div><p>Replimune's lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.</p>
<div class="lb-trans"><p>Replimune 的主要候選藥物 RP1，結合了 GM-CSF 和融合蛋白，以增強直接腫瘤溶解和免疫激活。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Replimune Group</li>
<li>Your Bank Account Is No Longer Safe</li>
<li>Ray Dalio Says Buy Gold. I Say Get Paid Every Month From It</li>
<li>1 Hour Once A Day</li>
<li>[No Brainer Gold Play]: “Show me a better investment.”</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Replimune Group</li>
<li>你的銀行賬户不再安全</li>
<li>雷·達里奧建議買黃金。我建議每月從中獲得收入</li>
<li>每天一次，持續一小時</li>
<li>[顯而易見的黃金投資]: “給我一個更好的投資。”</li>
<li>一位前 CIA 特工對即將到來的崩潰的看法</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVQTA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=REPL"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Replimune Group Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 $1,000 在 Replimune Group 嗎？</h2>
</div><p>Before you consider Replimune Group, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Replimune Group 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Replimune Group wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛的市場注意到之前購買的股票……而 Replimune Group 並不在名單上。</p>
</div><p>While Replimune Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Replimune Group 目前在分析師中被評為持有，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Replimune Group (REPL) 將在週三公佈季度收益